Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 154

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 154
---
    License Agreement by and between the Registrant and Brii Biosciences Limited, dated November 20, 2019.
     
    S-1
     
    333-263295
     
    10.14
     
    March 4, 2022

    10.15
     
    Amended and Restated Global Health Agreement by and among the Registrant, Adjuvant Global Health Technology Fund L.P., and Adjuvant Global Health Technology Fund DE L.P., dated March 5, 2021.
     
    S-1
     
    333-263295
     
    10.15
     
    March 4, 2022

91

    Incorporated by Reference

    ExhibitNumber
     
    Description
     
    Form
     
    File No.
     
    Exhibit
     
    Filing Date

    10.16#
     
    Offer Letter by and between the Registrant and Joshua Eizen, dated September 19, 2022.
     
    10-Q
     
    001-41331
     
    10.1
     
    November 9, 2022

    10.17#*
     
    AN2 Therapeutics, Inc. 2024 Amended Non-Employee Director Compensation Policy

    10.18‡*
     
    Exclusive Patent License Agreement, dated October 10, 2023, by and between the Registrant and the University of Georgia Research Foundation, Inc

    19.1*
     
    AN2 Therapeutics, Inc. 2022 Insider Trading Policy

    23.1*
     
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.

    24.1*
     
    Power of Attorney (incorporated by reference to the signature page to this Annual Report on Form 10-K.)

    31.1*
     
    ﻿Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2*
     
    ﻿Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Purs